Literature DB >> 30291804

A prospective comparison of cancer clinical trial availability and enrollment among adolescents/young adults treated at an adult cancer hospital or affiliated children's hospital.

Stefanie M Thomas1,2, Jemily Malvar1, Hanh Henry Tran3, Jared T Shows4, David R Freyer1,2,5.   

Abstract

BACKGROUND: Low cancer clinical trial (CCT) enrollment may contribute to survival disparities affecting adolescents and young adults (AYAs) (ages 15-39 years). The objective of this study was to evaluate whether differences in CCT availability related to treatment site could explain the low CCT enrollment.
METHODS: This prospective, observational cohort study was conducted at an academic children's hospital and its affiliated but geographically separated adult cancer hospital within a National Cancer Institute-designated Comprehensive Cancer Center. For consecutive, newly diagnosed AYA patients, it was determined whether an appropriate CCT existed nationally, was available at the treatment site, and was used for enrollment. Proportions of AYAs in these categories were compared between sites using the chi-square test.
RESULTS: One hundred fifty-two consecutive AYA patients were included from the children's hospital (n = 68; ages 15-20 years) and the adult cancer hospital (n = 84; ages 18-39 years). Although there was no difference in CCT existence for individual AYA patients by site (children's hospital [36 of 68 patients; 52.9%] vs adult cancer hospital [45 of 84 patients; 53.6%]; P = .938), CCT availability was significantly lower at the adult cancer hospital (14 of 84 patients [16.7%] vs 30 of 68 [44.1%] at the children's hospital; P < .001). The proportion of AYAs enrolled was low at both sites (8 of 68 patients [11.8%] vs 6 of 84 patients [7.1%], respectively; P = .327). Fewer existing CCTs were available at the adult cancer hospital (4 of 27 patients [14.8%] vs 8 of 14 patients [57.1%], respectively), and those were directed toward solid tumors and new agents.
CONCLUSIONS: Efforts to improve low CCT enrollment among AYAs should be differentiated by treatment site. In the adult setting, these efforts should be aimed at improving CCT availability by overcoming site-level barriers to opening existing CCTs.
© 2018 American Cancer Society.

Entities:  

Keywords:  adolescent; adolescents and young adults (AYAs); clinical oncology; clinical trial as topic; multicenter studies as topic; pediatric oncology; young adult

Mesh:

Year:  2018        PMID: 30291804      PMCID: PMC6234084          DOI: 10.1002/cncr.31727

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?

Authors:  Helen M Parsons; Linda C Harlan; Nita L Seibel; Jennifer L Stevens; Theresa H M Keegan
Journal:  J Clin Oncol       Date:  2011-09-19       Impact factor: 44.544

2.  Clinical research participation among adolescent and young adults at an NCI-designated Comprehensive Cancer Center and affiliated pediatric hospital.

Authors:  Stacy D Sanford; Jennifer L Beaumont; Mallory A Snyder; Jennifer Reichek; John M Salsman
Journal:  Support Care Cancer       Date:  2017-01-10       Impact factor: 3.603

3.  Regulatory barriers to clinical trial enrollment of adolescent and young adult oncology patients.

Authors:  Judy Felgenhauer; Mary C Hooke
Journal:  Pediatrics       Date:  2014-06       Impact factor: 7.124

Review 4.  Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies.

Authors:  Aaron R Weiss; Craig R Nichols; David R Freyer
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

5.  National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation.

Authors:  Archie Bleyer; Michael Montello; Troy Budd; Scott Saxman
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

6.  Who Treats Adolescents and Young Adults with Cancer? A Report from the AYA HOPE Study.

Authors:  Helen M Parsons; Linda C Harlan; Susanne Schmidt; Theresa H M Keegan; Charles F Lynch; Erin E Kent; Xiao-Cheng Wu; Stephen M Schwartz; Roland L Chu; Gretchen Keel; Ashley Wilder Smith
Journal:  J Adolesc Young Adult Oncol       Date:  2015-09       Impact factor: 2.223

7.  Funding oncology clinical trials: are cooperative group trials sustainable?

Authors:  Hsien-Yeang Seow; Patrick Whelan; Mark N Levine; Kathryn Cowan; Barbara Lysakowski; Brenda Kowaleski; Anne Snider; Rebecca Y Xu; Andrew Arnold
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

8.  Patterns of enrollment on cooperative group studies. An analysis of trends from the Los Angeles County Cancer Surveillance Program.

Authors:  M D Krailo; L Bernstein; J Sullivan-Halley; G D Hammond
Journal:  Cancer       Date:  1993-05-15       Impact factor: 6.860

9.  Different rates of clinical trial enrollment between adolescents and young adults aged 15 to 22 years old and children under 15 years old with cancer at a children's hospital.

Authors:  Peter H Shaw; Arthur Kim Ritchey
Journal:  J Pediatr Hematol Oncol       Date:  2007-12       Impact factor: 1.289

10.  Case-linked analysis of clinical trial enrollment among adolescents and young adults at a National Cancer Institute-designated comprehensive cancer center.

Authors:  Chelsea L Collins; Jemily Malvar; Ann S Hamilton; Dennis M Deapen; David R Freyer
Journal:  Cancer       Date:  2015-09-22       Impact factor: 6.921

View more
  7 in total

1.  Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial.

Authors:  Nupur Mittal; Anne-Marie Langevin; Wade Kyono; David S Dickens; Allison Grimes; John M Salsman; Brad H Pollock; Michael Roth
Journal:  J Adolesc Young Adult Oncol       Date:  2021-05-13       Impact factor: 2.223

2.  Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.

Authors:  Michael Roth; Melissa Beauchemin; Justine M Kahn; Archie Bleyer
Journal:  Cancer Med       Date:  2021-09-30       Impact factor: 4.452

3.  Comparing Barriers and Facilitators to Adolescent and Young Adult Clinical Trial Enrollment Across High- and Low-Enrolling Community-Based Clinics.

Authors:  Elizabeth J Siembida; Holli A Loomans-Kropp; Irene Tami-Maury; David R Freyer; Lillian Sung; Howland E Crosswell; Brad H Pollock; Michael E Roth
Journal:  Oncologist       Date:  2022-05-06       Impact factor: 5.837

4.  Barriers and Facilitators to Adolescent and Young Adult Cancer Trial Enrollment: NCORP Site Perspectives.

Authors:  Elizabeth J Siembida; Holli A Loomans-Kropp; Irene Tami-Maury; David R Freyer; Lillian Sung; Howland E Crosswell; Brad H Pollock; Michael E Roth
Journal:  JNCI Cancer Spectr       Date:  2021-03-22

Review 5.  Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention.

Authors:  Elizabeth J Siembida; Holli A Loomans-Kropp; Neha Trivedi; Ann O'Mara; Lillian Sung; Irene Tami-Maury; David R Freyer; Michael Roth
Journal:  Cancer       Date:  2019-12-23       Impact factor: 6.921

6.  Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute-Designated Community Oncology Research Programs.

Authors:  David S Dickens; Michael E Roth; Brad H Pollock; Anne-Marie Langevin
Journal:  JCO Oncol Pract       Date:  2020-05-12

7.  Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia.

Authors:  Justine A Ellis; Vajiranee S Malalasekera; Christie Allan; Peter F Choong; Jordan R Hansford; Ryan Hehir; Natasha Morello; Sally O'Callaghan; Lisa Orme; Nitya Phillipson; Mark A Rosenthal; Susan Sawyer; Robyn Strong; Leanne Super; Angela Watt; Chris Williams; Anne Woollett; Alexandra Robertson; Jeremy Lewin
Journal:  J Adolesc Young Adult Oncol       Date:  2021-07-22       Impact factor: 1.757

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.